Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of ADvantage Therapeutics.

    Client Virtual Booth

    ADVANTAGE THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    ADvantage Therapeutics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Miami, Florida
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://advantagetherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/in/advantage-therapeutics-inc-47b23522b/
    Twitter
    Twitter
    https://twitter.com/ADvantageTx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    ADvantage Therapeutics Has Commenced Enrollment for Its Phase 2b Clinical Trial of AD04 for Treatment of Alzheimer's Disease

    Details:

    AD04 is a novel immunotherapy for mild alzheimer’s disease. The compound has been used as an adjuvant in human and animal vaccination programs. It has demonstrated significantly slower decline in hippocampal volume as a biomarker.


    Lead Product(s): AD04

    Therapeutic Area: Neurology Product Name: AD04

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 27, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    ADvantage Therapeutics Secures Approvals for Clinical Trial of AD04 in Alzheimer’s Disease Treatment in Poland, Bulgaria, and Slovakia

    Details:

    AD04 (alhydrogel) is a novel immunotherapy for early alzheimer’s disease. The compound has been used as an adjuvant in human and animal vaccination programs. It has demonstrated significantly slower decline in hippocampal volume as a biomarker.


    Lead Product(s): Aluminium Hydroxide

    Therapeutic Area: Neurology Product Name: AD04

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 20, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04 for Phase 2b Trial in Alzheime...

    Details:

    AD04™ (alhydrogel) is a novel immunotherapy for mild Alzheimer’s Disease under the Innovative Licensing and Access Pathway (ILAP). AD04™ also showed slower decline in hippocampal volume as a biomarker.


    Lead Product(s): Aluminium Hydroxide

    Therapeutic Area: Neurology Product Name: AD04

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 05, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    ADvantage Therapeutics Developing Therapies to Treat Neurodegenerative Conditions with Focus on Alzheimer’s Disease

    Details:

    AD04™ (alhydrogel) is a novel immunotherapy for early alzheimer’s disease. The compound has been used as an adjuvant in human and animal vaccination programs. It has demonstrated significantly slower decline in hippocampal volume as a biomarker.


    Lead Product(s): Aluminium Hydroxide

    Therapeutic Area: Neurology Product Name: AD04

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 15, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    minakem-m-2024-05-27

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search